{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:01:07Z","timestamp":1789758067629,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jacadv.2025.102022","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:35:55Z","timestamp":1753950955000},"page":"102022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Christopher","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Pailer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Spannbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardin","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza Veronika","family":"Braser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00fclsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-0996","authenticated-orcid":false,"given":"Christian","family":"Gerges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gottsauner-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-0361","authenticated-orcid":false,"given":"Mariann","family":"Gy\u00f6ngy\u00f6si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Riesenhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-1380","authenticated-orcid":false,"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-8598","authenticated-orcid":false,"given":"Thomas A.","family":"Zelniker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacadv.2025.102022_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"6382","key":"10.1016\/j.jacadv.2025.102022_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102022_bib3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10124","key":"10.1016\/j.jacadv.2025.102022_bib4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"48","key":"10.1016\/j.jacadv.2025.102022_bib5","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacadv.2025.102022_bib6","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102022_bib7","first-page":"21","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment","volume":"8","author":"Andres","year":"2022","journal-title":"Cardiooncology"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102022_bib8","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer \u2013 a scientific statement of the Heart Failure Association ( HFA ) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10.1016\/j.jacadv.2025.102022_bib9","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102022_bib10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.jacadv.2025.102022_bib11","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1093\/eurheartj\/ehz587","article-title":"The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study","volume":"40","author":"Van\u2019T Klooster","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102022_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","article-title":"Common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis","volume":"3","author":"Leiva","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102022_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaccao.2024.04.006","article-title":"Cancer therapy and exercise intolerance: the heart is but a part","volume":"6","author":"Dillon","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"23","key":"10.1016\/j.jacadv.2025.102022_bib14","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102022_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/heartjnl-2015-307894","article-title":"Roadmap for biomarkers of cancer therapy cardiotoxicity","volume":"102","author":"Yu","year":"2016","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102022_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer","volume":"1","author":"Chitturi","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102022_bib17","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.jacc.2020.03.067","article-title":"Mechanistic biomarkers informative of both cancer and cardiovascular disease","volume":"75","author":"Narayan","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102022_bib18","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.jtha.2024.07.019","article-title":"Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study","volume":"22","author":"Kraler","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102022_bib19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"10.1016\/j.jacadv.2025.102022_bib20","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102022_bib21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.jacadv.2025.102022_bib22","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of immune checkpoint inhibitor\u2013based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial","volume":"40","author":"Rini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102022_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102022_bib24","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ehf2.13930","article-title":"Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation","volume":"9","author":"Hofer","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102022_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102022_bib26","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102022_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1062858","article-title":"Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors","volume":"9","author":"Torrente","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"29","key":"10.1016\/j.jacadv.2025.102022_bib28","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102022_bib29","doi-asserted-by":"crossref","first-page":"4771785","DOI":"10.21037\/qims-22-41","article-title":"Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study","volume":"12","author":"Liu","year":"2022","journal-title":"Quant Imaging Med Surg"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102022_bib30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor\u2013induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.jacadv.2025.102022_bib31","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25004466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25004466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:45:48Z","timestamp":1764161148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25004466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2772963X25004466"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102022","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102022"}}